Takotsubo syndrome after BNT162b2 mRNA Covid-19 vaccine: Emotional or causative relationship with vaccination?

Takotsubo syndrome after BNT162b2 mRNA Covid-19 vaccine: Emotional or causative relationship with vaccination?

Bibliographic Details
Main Authors:	Andrea Tedeschi, Massimiliano Camilli, Umberto Ianni, Giovanni Tavecchia, Matteo Palazzini, Iside Cartella, Piero Gentile, Giuseppina Quattrocchi, Francesca Maria Spanò, Manlio Cipriani, Andrea Garascia, Enrico Ammirati
Format:	Article
Language:	English
Published:	Elsevier 2022-06-01
Series:	International Journal of Cardiology: Heart & Vasculature
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352906722000513

Similar Items

SARS-CoV2 infections in heart transplant recipients: Vaccines still are our greatest weapon
by: Andrea Tedeschi, et al.
Published: (2024-04-01)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Xin Rong Lim, et al.
Published: (2021-08-01)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
by: Rieke Reiter, et al.
Published: (2022-05-01)

Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence?
by: Giulia Renisi, et al.
Published: (2021-09-01)

Acute myocarditis following administration of BNT162b2 vaccine
by: Mhd Baraa Habib, et al.
Published: (2021-01-01)

Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine
by: Andrea Lombardi, et al.
Published: (2022-01-01)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
by: Stilla Bauernfeind, et al.
Published: (2021-09-01)

Reactive arthritis following COVID-19 vaccination with BNT162b2
by: Emily Lebowitz, MD, et al.
Published: (2022-06-01)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
by: Louise Murdoch, et al.
Published: (2023-09-01)

To vaccinate or not to vaccinate – BNT162b2 seroconversion rate and side effects among Polish healthcare workers
by: Bartosz Siewert, et al.
Published: (2022-09-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

BNT162b2 COVID-19 Vaccination and Its Effect on Blood Pressure
by: Toh Leong Tan, et al.
Published: (2022-12-01)

Extended interval BNT162b2 vaccination enhances peak antibody generation
by: Helen Parry, et al.
Published: (2022-01-01)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
by: Ryoichi Miyazaki, et al.
Published: (2023-02-01)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
by: Chi-Yan Lam, et al.
Published: (2023-07-01)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
by: Tekin Guney, et al.
Published: (2022-02-01)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
by: Sabina Zurac, et al.
Published: (2022-07-01)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
by: Esther Saiag, et al.
Published: (2021-12-01)

Mucosal immune response in BNT162b2 COVID-19 vaccine recipients
by: Lorenzo Azzi, et al.
Published: (2022-01-01)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
by: Takeshi Terashima
Published: (2021-01-01)

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany
by: Tatjana Schwarz, et al.
Published: (2021-08-01)

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.
by: Natalia Vargas-Herrera, et al.
Published: (2022-01-01)

Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
by: Luca Coppeta, et al.
Published: (2021-08-01)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
by: Simone Barocci, et al.
Published: (2022-03-01)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
by: Eun-Ju Kim, et al.
Published: (2023-06-01)

Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
by: Ilias Mavrovouniotis, et al.
Published: (2023-02-01)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
by: Payne, RP, et al.
Published: (2021)

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan
by: Mitsuhiro Nagano, et al.
Published: (2024-12-01)

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS
by: R. Gurion, et al.
Published: (2022-06-01)

Hemophagocytic Lymphohistiocytosis Following BNT162b2 mRNA COVID-19 Vaccination
by: Ting-Yu Lin, et al.
Published: (2022-04-01)

Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
by: Suyanee Mansanguan, et al.
Published: (2022-08-01)

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome
by: Diletta Valentini, et al.
Published: (2022-01-01)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
by: Giovanna Cocomazzi, et al.
Published: (2021-08-01)

Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability
by: Elizabeth K. Graydon, et al.
Published: (2023-08-01)

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19
by: Maria Eduarda Andrade e Andrade, et al.
Published: (2022-01-01)

Insulin allergy manifesting soon after COVID‐19 vaccination (BNT162b2)
by: Hiroshi Komamura, et al.
Published: (2023-03-01)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
by: Toshinori Nishizawa, et al.
Published: (2022-09-01)

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
by: Nicola Silvestris
Published: (2021-12-01)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
by: Fulvia Pimpinelli, et al.
Published: (2021-07-01)

Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies
by: Donato Amodio, et al.
Published: (2021-10-01)